LONDON, January 5, 2018 /PRNewswire/ --
The global botanical and plant-derived drugs market is expected to grow at a CAGR of 6.8% in the first half of the forecast period. In 2016, the phenols submarket held 30.2% of the global botanical and plant-derived drugs market.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 164-page report you will receive 70 tables and 82 figures- all unavailable elsewhere.
The 164-page report provides clear detailed insight into the global botanical and plant-derived drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Botanical and Plant-derived Drugs Market forecast to 2027
• This report also breaks down the revenue forecast for global botanical and plant-derived drugs market by type: - Steroids - Phenols - Terpenes - Glycosides - Others
This report provides a SWOT analysis for each submarket.
• This report also breaks down the revenue forecast for global botanical and plant-derived drugs market by application: - Hormone Diseases - Infectious Diseases - Pain & Central Nervous System Disorders - Cardiovascular & Metabolic Diseases - Respiratory & Oncology Diseases
• Our work also shows individual revenue forecasts to 2027 for these regional and national markets - North America: US & Canada - Europe: Germany, France, the UK, Italy, Spain, Rest of Europe - Asia-Pacific: China, Japan, India, Rest of APAC - Latin America: Brazil, Mexico, Rest of Latin America - Middle East & Africa: Saudi Arabia, South Africa, Rest of Middle East & Africa
Each regional market if further segmented by type and by application.
• This report discusses several brands, including: - Sativex (GW Pharmaceuticals) - Marinol (Unimed Pharmaceuticals) - Nabilone / Cesamet (Valeant Pharmaceuticals) - Dexanabinol (Solvay Pharmaceuticals, acquire by Abbott Laboratories) - CT-3 (Indevus Pharmaceuticals) - Cannabinor (Pharmos) - HU 308 (Pharmos) - HU 331 (Cayman Chemical) - Rimonabant / Acomplia (Sanofi-Aventis) - Taranabant / MK-0364 (Merck & Co.)
• This report assesses several leading companies that manufacture and market botanical and plant-derived drugs, including: - Abbott Laboratories - Bayer AG - Eli Lilly - Johnson & Johnson - Novartis AG - Pfizer, Inc. - Bristol-Myers Squibb (BMS) - Medigene AG
• This report also discusses the Drivers and Restraints of the global botanical and plat derived-drugs market.
Visiongain's study is for everybody needing commercial analyses for the global botanical and plat derived-drugs market. You will find data, trends and predictions. Please order our report now.
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website:
https://www.visiongain.com/Report/2092/Botanical-and-Plant-Derived-Drugs-Market-Forecast-to-2027
List of Companies and Organisations Mentioned
Abbott Laboratories
AbCellera Biologics, Inc.
Abott Laboratories
Accelis Pharma
Alere, Inc.
Almirall, S.A.
Array BioPharma
Arzneimittelwerk
Asia Journal of Cancer Prevention
Baader Bank AG
Baxter International
Bayer AG
Bristol-Myers Squibb
Canadian Cancer Society
Cancer Research UK
Cayman Chemical
Centre for Chronic Disease Control & Prevention
China's Ministry of Health (MOH)
Eli Lilly and Company
EUFETS GmbH
European Medicines Agency
European PD Association (EPDA)
European Union
Food and Drug Administration (FDA)
Fougera Pharmaceuticals, inc.
Guggenheim Securities, LLC
GW Pharmaceuticals
Hospira
Indevus Pharmaceuticals
Indian Council of Medical Research (ICMR)
Institute for Health Metrics and Evaluation
International Agency for Research on Cancer (IARC)
Istat
Janssen Products, LP
Johnson & Johnson
McKinsey & Co
Medigene AG
Merck
Mitsui Norin Co. Ltd
National Center for Biotechnology Information (NCBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Health
National Kidney Foundation
Novartis International AG
Organisation for Economic Co-operation and Development (OECD)
Otsuka Pharmaceutical
Paladin Labs Inc.
Pfizer, Inc.
Pharmos
Press Information Bureau
Rome Foundation
Sandoz Inc.,
Sanofi S.A.
Solvay Pharmaceuticals
Solvay Pharmaceuticals
The United Nations
The World Bank
Trout Capital LLC
UNICANCER
Unimed Pharmaceuticals
US. National Cancer Institute
Valeant Pharmaceuticals International
World Health Organization
World Heart Federation
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
Prospects for Leading Companies in Steroids, Phenols, Terpenes, Glycosides and Others, Sativex, Marinol Nabilone, Dexanabinol, CT-3, Cannabinor, HU 308, HU 331, Rimonabant, Taranabant
Advertisement
The global botanical and plant-derived drugs market is expected to grow at a CAGR of 6.8% in the first half of the forecast period. In 2016, the phenols submarket held 30.2% of the global botanical and plant-derived drugs market.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 164-page report you will receive 70 tables and 82 figures- all unavailable elsewhere.
The 164-page report provides clear detailed insight into the global botanical and plant-derived drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Botanical and Plant-derived Drugs Market forecast to 2027
• This report also breaks down the revenue forecast for global botanical and plant-derived drugs market by type: - Steroids - Phenols - Terpenes - Glycosides - Others
This report provides a SWOT analysis for each submarket.
• This report also breaks down the revenue forecast for global botanical and plant-derived drugs market by application: - Hormone Diseases - Infectious Diseases - Pain & Central Nervous System Disorders - Cardiovascular & Metabolic Diseases - Respiratory & Oncology Diseases
• Our work also shows individual revenue forecasts to 2027 for these regional and national markets - North America: US & Canada - Europe: Germany, France, the UK, Italy, Spain, Rest of Europe - Asia-Pacific: China, Japan, India, Rest of APAC - Latin America: Brazil, Mexico, Rest of Latin America - Middle East & Africa: Saudi Arabia, South Africa, Rest of Middle East & Africa
Each regional market if further segmented by type and by application.
• This report discusses several brands, including: - Sativex (GW Pharmaceuticals) - Marinol (Unimed Pharmaceuticals) - Nabilone / Cesamet (Valeant Pharmaceuticals) - Dexanabinol (Solvay Pharmaceuticals, acquire by Abbott Laboratories) - CT-3 (Indevus Pharmaceuticals) - Cannabinor (Pharmos) - HU 308 (Pharmos) - HU 331 (Cayman Chemical) - Rimonabant / Acomplia (Sanofi-Aventis) - Taranabant / MK-0364 (Merck & Co.)
• This report assesses several leading companies that manufacture and market botanical and plant-derived drugs, including: - Abbott Laboratories - Bayer AG - Eli Lilly - Johnson & Johnson - Novartis AG - Pfizer, Inc. - Bristol-Myers Squibb (BMS) - Medigene AG
• This report also discusses the Drivers and Restraints of the global botanical and plat derived-drugs market.
Visiongain's study is for everybody needing commercial analyses for the global botanical and plat derived-drugs market. You will find data, trends and predictions. Please order our report now.
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website:
https://www.visiongain.com/Report/2092/Botanical-and-Plant-Derived-Drugs-Market-Forecast-to-2027
List of Companies and Organisations Mentioned
Abbott Laboratories
AbCellera Biologics, Inc.
Abott Laboratories
Accelis Pharma
Alere, Inc.
Almirall, S.A.
Array BioPharma
Arzneimittelwerk
Asia Journal of Cancer Prevention
Baader Bank AG
Baxter International
Bayer AG
Bristol-Myers Squibb
Canadian Cancer Society
Cancer Research UK
Cayman Chemical
Centre for Chronic Disease Control & Prevention
China's Ministry of Health (MOH)
Eli Lilly and Company
EUFETS GmbH
European Medicines Agency
European PD Association (EPDA)
European Union
Food and Drug Administration (FDA)
Fougera Pharmaceuticals, inc.
Guggenheim Securities, LLC
GW Pharmaceuticals
Hospira
Indevus Pharmaceuticals
Indian Council of Medical Research (ICMR)
Institute for Health Metrics and Evaluation
International Agency for Research on Cancer (IARC)
Istat
Janssen Products, LP
Johnson & Johnson
McKinsey & Co
Medigene AG
Merck
Mitsui Norin Co. Ltd
National Center for Biotechnology Information (NCBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Health
National Kidney Foundation
Novartis International AG
Organisation for Economic Co-operation and Development (OECD)
Otsuka Pharmaceutical
Paladin Labs Inc.
Pfizer, Inc.
Pharmos
Press Information Bureau
Rome Foundation
Sandoz Inc.,
Sanofi S.A.
Solvay Pharmaceuticals
Solvay Pharmaceuticals
The United Nations
The World Bank
Trout Capital LLC
UNICANCER
Unimed Pharmaceuticals
US. National Cancer Institute
Valeant Pharmaceuticals International
World Health Organization
World Heart Federation
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
